Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

Twelve-week efalizumab treatment resulted in significant improvement; extension of therapy to 24 weeks resulted in additional improvement in patients who initially had not achieved PASI-75. There were no significant changes in safety profile during weeks 13-24.